Dual GLP-1 and glucagon receptor mechanism

Two receptors, two organs, one weekly signal

Survodutide works by switching on two receptors that sit in different places. The GLP-1 receptor is spread across the brain, pancreas, and gut; the glucagon receptor lives mostly on the liver. This unit maps where each arm acts, then builds the biology underneath: why the insulin boost is glucose-dependent, why the glucagon signal is kept partial, and how the body reveals that both arms are engaged.

This is the mechanistic core the trial units later test against real outcomes. Get the two-receptor picture clear here, and the obesity, MASH, and safety data all read as consequences of it.